Confronting the Clinical and Economic Burden of Atopic Dermatitis: Managed Care Considerations on the Role of New and Emerging Therapies

Confronting the Clinical and Economic Burden of Atopic Dermatitis: Managed Care Considerations on the Role of New and Emerging Therapies is organized by National Association of Managed Care Physicians (NAMCP).,This activity is valid from August 1, 2022, to August 1, 2023,Description:,Atopic dermatitis is a common chronic inflammatory skin disease characterized by persistent itching that can severely affect the quality of life. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Our improved understanding of the pathophysiology underlying atopic dermatitis is resulting in the development of targeted therapies for children and adult patients with this disease. There are approximately 17.8 million people with eczema or atopic dermatitis in the United States. Older treatments adequately care for patients with atopic dermatitis, but have shown problems with sustained efficacy in patients with eczema or atopic dermatitis. Fortunately for patients with this disease, several new treatments have recently become available, including JAK inhibitors, that have shown improved efficacy and safety, offering patients the potential for improved outcomes and quality of life. This activity will focus on new and emerging potential therapies, how clinicians can potentially integrate them into the treatment paradigm, what managed care professionals and payors need to know about these new options and information on the mechanisms of action of these agents. With so many new options becoming potentially available in the management of atopic dermatitis, it is critical that physician medical directors, payers, pharmacy directors, pharmacists, nurse case managers, and other HCPs are updated on the safety and efficacy data on these emerging options, possible strategies for implementing them into the treatment paradigm, and key points that managed care professionals need to know, which will ultimately improve patient outcomes.,Upon completion of this activity, participants will be able to:,• Explore the unmet clinical and economic needs in atopic dermatitis (AD) and the impact of inadequately treated disease on physical and mental health, quality of life, costs, and work productivity,• Examine atopic dermatitis including the Janus kinase signal transducer and activator of transcription (JAK-STAT) pathophysiology, range of clinical symptoms/severity, and challenges with current standard therapies,• Describe the immunopathogenic mechanisms of AD and the rationale for targeting the relevant cytokines, including IL-13,• Compare and contrast efficacy and safety profiles of novel therapeutics in AD, including IL-13 antagonists and JAK inhibitors, in a range of patient populations,• Analyze the evolving role of new and emerging IL-13 antagonists and JAK inhibitors in the management of AD,• Review strategies for anticipating, recognizing, and managing adverse events of newer therapy in patients with AD outcomes